文献速递肝病

终末期肝病患者MELD 3.0评分超过40分时的死亡率

Mortality in patients with end-stage liver disease above model for end-stage liver disease 3.0 of 40.
PubMed 文献 · Hepatology · 2023-02-17

该研究基于器官获取与移植网络注册数据,分析2016年1月至2021年12月成人肝移植等待者,发现MELD 3.0≥40分者30天等待名单死亡率随评分升高而增加,40-44分为58.3%,≥50分为82.4%,每增加1分多变量风险比为1.13,移植后生存率在各MELD分层间相当。

要点

  • MELD 3.0≥40分等待者30天死亡率随评分升高而增加,40-44分为58.3%,≥50分为82.4%。
  • 校正慢加急性肝衰竭等变量后,MELD 3.0每增加1分风险比为1.13。
  • 移植后生存率在包括35-39分在内的各MELD分层间相当。

核心结论

  • MELD 3.0评分超过40分与等待名单死亡率增加相关,且不 adversely 影响移植后结局。
  • 取消等待名单候选者MELD评分上限可能使肝移植带来更大的生存获益。

研究设计与样本

  • 研究基于器官获取与移植网络注册数据,纳入2016年1月至2021年12月成人肝移植等待名单登记。
  • 研究期间共有54060例新等待名单登记,其中2820例(5.2%)在登记时MELD 3.0≥40分。
  • 所有MELD 3.0评分在登记时及之后计算,评估最长30天等待名单死亡率和移植后生存率。

主要发现

  • MELD 3.0≥40分患者30天等待名单死亡率高,且随MELD 3.0评分升高至55分进一步增加。
  • 30天死亡率:MELD 3.0 40-44分为58.3%,≥50分为82.4%。
  • 校正包括慢加急性肝衰竭在内的多个变量后,MELD 3.0每增加1分的多变量风险比为1.13。
  • 移植时MELD 40分的肝移植受者数量从2002年的155例增加至2021年的752例。
  • 移植后生存率在包括MELD 35-39分在内的各MELD分层间相当。

临床怎么用

  • 原文结论指出,取消等待名单候选者MELD评分上限可能使肝移植带来更大的生存获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Since the implementation of the model for end-stage liver disease (MELD) score to determine waitlist priority for liver transplant (LT) in 2002, the score has been capped at 40. Recently, the MELD 3.0 score was proposed to improve upon MELD-Na. Here, we examine waitlist mortality and LT outcomes in patients with MELD 3.0 ≥ 40 to assess the potential impact of uncapping the score. APPROACH AND RESULTS: Adult waitlist registrations for LT from January 2016 to December 2021 were identified in the registry data from the Organ Procurement and Transplant Network. All MELD 3.0 scores were calculated at registration and thereafter. Waitlist mortality for up to 30 days was calculated as well as post-LT survival. There were 54,060 new waitlist registrations during the study period, of whom 2820 (5.2%) had MELD 3.0 ≥ 40 at listing. The 30-day waitlist mortality was high in these patients, yet it increased further in proportion with MELD 3.0 up to a score of 55 with 30-day mortality of 58.3% for MELD 3.0 of 40-44 and 82.4% for ≥50. The multivariable hazard ratio was 1.13 for each point of MELD 3.0, adjusting for several variables including acute-on-chronic liver failure. The number of LT recipients with MELD 40 at transplant increased from 155 in 2002 to 752 in 2021. Posttransplant survival was comparable across MELD strata including MELD of 35-39. CONCLUSION: MELD 3.0 scores beyond 40 are associated with increasing waitlist mortality without adversely affecting posttransplant outcome. Uncapping the MELD score in waitlist candidates may lead to greater survival benefit from LT.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Kim WR, Mannalithara A, Kwo PY, et al. Mortality in patients with end-stage liver disease above model for end-stage liver disease 3.0 of 40. Hepatology. 2023. PMID: 36052665. doi:10.1002/hep.32770

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。